Literature DB >> 28530307

Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28530307     DOI： 10.1111/vco.283

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN： 1476-5810            Impact factor:   2.613


× No keyword cloud information.
  136 in total

1.  Successful management of doxorubicin overdose and extravasation in a dog with lymphoma.

Authors:  Kristin S Kicenuik; Nicole C Northrup; Dawn M Clarke; Lisa J Bazzle
Journal:  Can Vet J       Date:  2018-10       Impact factor: 1.008

2.  Occult tonsillar squamous cell carcinoma in 2 dogs presenting for treatment of primary oral squamous cell carcinoma.

Authors:  Nicholas J Rancilio; Christopher M Fulkerson
Journal:  Can Vet J       Date:  2018-10       Impact factor: 1.008

Review 3.  Defining the Value of a Comparative Approach to Cancer Drug Development.

Authors:  Amy K LeBlanc; Christina N Mazcko; Chand Khanna
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

4.  Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.

Authors:  S Anthony Kahn; Christine M Mullin; Louis-Philippe de Lorimier; Kristine E Burgess; Rebecca E Risbon; Rogers M Fred; Kenneth Drobatz; Craig A Clifford
Journal:  Can Vet J       Date:  2013-03       Impact factor: 1.008

5.  A retrospective study of proteinuria in dogs receiving toceranib phosphate.

Authors:  Sindy L Piscoya; Kelly R Hume; Cheryl E Balkman
Journal:  Can Vet J       Date:  2018-06       Impact factor: 1.008

6.  Long-term clinical control of feline pancreatic carcinoma with toceranib phosphate.

Authors:  Andrea M Dedeaux; Ingeborg M Langohr; Bonnie B Boudreaux
Journal:  Can Vet J       Date:  2018-07       Impact factor: 1.008

7.  Nanomedicine for Spontaneous Brain Tumors: A Companion Clinical Trial.

Authors:  Hamed Arami; Chirag B Patel; Steven J Madsen; Peter J Dickinson; Ryan M Davis; Yitian Zeng; Beverly K Sturges; Kevin D Woolard; Frezghi G Habte; Demir Akin; Robert Sinclair; Sanjiv S Gambhir
Journal:  ACS Nano       Date:  2019-02-04       Impact factor: 15.881

8.  NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.

Authors:  Jenna H Burton; Christina Mazcko; Amy LeBlanc; Joseph M Covey; Jiuping Ji; Robert J Kinders; Ralph E Parchment; Chand Khanna; Melissa Paoloni; Sue Lana; Kristen Weishaar; Cheryl London; William Kisseberth; Erika Krick; David Vail; Michael Childress; Jeffrey N Bryan; Lisa Barber; E J Ehrhart; Michael Kent; Timothy Fan; Kelvin Kow; Nicole Northup; Heather Wilson-Robles; Joseph Tomaszewski; Julianne L Holleran; Miguel Muzzio; Julie Eiseman; Jan H Beumer; James H Doroshow; Yves Pommier
Journal:  Clin Cancer Res       Date:  2018-07-30       Impact factor: 12.531

9.  Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.

Authors:  T Laver; C A London; D M Vail; B J Biller; J Coy; D H Thamm
Journal:  Vet Comp Oncol       Date:  2017-06-15       Impact factor: 2.613

10.  Consensus recommendations on standardized magnetic resonance imaging protocols for multicenter canine brain tumor clinical trials.

Authors:  Rebecca A Packer; John H Rossmeisl; Michael S Kent; John F Griffin; Christina Mazcko; Amy K LeBlanc
Journal:  Vet Radiol Ultrasound       Date:  2018-03-09       Impact factor: 1.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.